FLUO.ST is trading 9.3% down at $38.10 as investors digest positive but early-stage Phase 2 data for its lead imaging agent, FG001.
- The company announced that its oral, head, and neck cancer trial met the primary endpoint and identified 0.30 mg/kg as the optimal dose, marking a key development milestone.
- Despite the positive results, the stock is seeing significant volatility and profit-taking as investors weigh the remaining clinical and regulatory risks ahead.